Skip to main content

Table 1 Baseline characteristics of the patients receiving educational materials and SMS texting (mHealth)

From: Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth

Characteristics

Non-contacted group

n = 450

Contacted group

n = 1062

Total

N = 1512

Age in yearsa

 16–25

104 (25.11)

240 (22.60)

344 (22.75)

 26–35

129 (28.67)

267 (25.14)

396 (26.19)

 36–45

97 (21.56)

260 (24.48)

357 (23.61)

 46–83

120 (26.67)

295 (27.78)

415 (27.45)

Gender (% male)a

285 (63.33)

641 (60.36)

926 (61.24)

Ethnicity (%)a

   

 White

7 (1.56)

37 (3.48)

44 (2.91)

 Pardo (mixed)

365 (81.11)

852 (80.23)

1217 (80.49)

 Indigenous

1 (0.22)

0 (0.00)

1 (0.07)

 Black

11 (2.44)

40 (3.77)

51 (3.37)

 Yellow

3 (0.67)

9 (0.85)

12 (0.79)

 Unknown

63 (14.00)

124 (11.68)

187 (12.37)

Type of malariaa

   

 P. Vivax

444 (98.67)

1,046 (98.49)

1490 (98.54)

 P. Falciparum

5 (1.11)

8 (0.75)

13 (0.96)

 Mixed infection/other

1 (0.22)

8 (0.75)

9 (0.60)

Treatment regimena

   

 Long standard regimen CQ + PQb

19 (4.22)

23 (2.17)

42 (2.78)

 Short standard regimen QC + PQc

425 (94.44)

1025 (96.52)

1450 (95.90)

 Combined therapy AT + PQd

5 (1.11)

7 (0.66)

12 (0.79)

 Mixed malaria schemef

1 (0.22)

7 (0.66)

8 (0.53)

  1. CQ: chloroquine; PQ: primaquine; AT: artemisin; a No statistically significant difference between contacted and uncontacted groups (P ≥ 0.05); b Long standard regimen: Chloroquine 25 mg / kg weight divided in 3 days (1500 mg adult dose) + Primaquine 0.25 mg / kg weight for 14 days (15 mg per day); c Short standard regimen: chloroquine for three days (10 mg / kg on day 1 and 7.5 mg / kg on days 2 and 3) + Primaquine 0.50 mg / kg weight for 7 days (30 mg per day); d Combined therapy based on Artemisin + Primaquine (single dose) 3 days; f Mixed malaria scheme: Artemisinin + Primaquine 2 tablet of 15 mg (single daily dose) for 7 days (double dose)